Flowtown has a terrific (and large!) graphic entitled "The New Marketing Trifecta." The trifecta refers to the three ways companies should (or could) be marketing their products and services. These are eMail,…
Bloomberg has a good round up of several emerging pharmaceutical companies developing antibiotics. As the article notes, Big Pharma has largely moved away from antibiotic development for a number of…
There is an excellent editorial in the May issue of Nature Biotechnology entitled Inadequately met needs. In it, the author points out that the US is moving away from innovative,…
Today's In Vivo Blog post summarizes comments that we have been hearing from our clients as well. Namely, that deals are increasingly shifting towards back-ended Royalties and earn-outs, at the…
This is a fantastic piece in Nature by Anu Acharya, CEO of Ocimum Biosolutions in India. I recommend reading the article in full. A few key points that struck us…
This week we learn that two novel pain medications will never see the light of day: Novartis had reached the market with the COX-II inhibitor Prexige (rebranded as the unusually…
We regret that we were unable to attend the panel discussions at BioTrinity last week. However, an excellent summary was posted on the PharmaPhorum web site. Of note: 1. Investment…
Last week, Lacerta Bio attended the annual BioTrinity Partnering and Investment Conference in Newbury, UK. This was our first time at this conference. So how was the conference? A few…
Fred Frank, a highly respected investment banker, greeted us on Tuesday morning with this missive: Venture capitalists, who make high-risk investments in start-ups, are tired of waiting years for biotech companies…
It was recently announced that the EMA has rejected Xyrem for the treatment of fibromyalgia. Interestingly, Xyrem is already approved in Europe for the treatment of narcolepsy with cataplexy. We…